{"protocolSection": {"identificationModule": {"nctId": "NCT01290887", "orgStudyIdInfo": {"id": "C38072/3085"}, "secondaryIdInfos": [{"id": "2010-024540-15", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}, "briefTitle": "Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma", "officialTitle": "An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients With Eosinophilic Asthma Who Completed a Prior Teva-Sponsored Study in Eosinophilic Asthma"}, "statusModule": {"statusVerifiedDate": "2016-04", "overallStatus": "TERMINATED", "whyStopped": "Business decision", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-06"}, "primaryCompletionDateStruct": {"date": "2015-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-02-04", "studyFirstSubmitQcDate": "2011-02-04", "studyFirstPostDateStruct": {"date": "2011-02-07", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-03-23", "resultsFirstSubmitQcDate": "2016-04-28", "resultsFirstPostDateStruct": {"date": "2016-06-06", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2015-10-21", "dispFirstSubmitQcDate": "2015-10-21", "dispFirstPostDateStruct": {"date": "2015-11-01", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-04-28", "lastUpdatePostDateStruct": {"date": "2016-06-06", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The primary objective of the study is to evaluate the long-term safety of reslizumab at a dosage of 3.0 mg/kg every 4 weeks for approximately 24 months in pediatric and adult patients with eosinophilic asthma as assessed by adverse events, physical examination findings, vital sign measurements, and concomitant medication usage throughout the study (every 4 weeks), clinical laboratory test results, and measurement of antidrug antibodies.", "detailedDescription": "Study patients deemed eligible based on activities from the preceding Teva sponsored double blind study of reslizumab in eosinophilic asthma. Specifically, as per inclusion criterion c, patients must have either completed treatment in a previous Teva-sponsored study or have received at least 2 doses of study drug treatment in a pulmonary function study.\n\nEligible patients could enroll in this study only after completion of the end of treatment visit in a Teva sponsored, randomized, placebo controlled, double blind study of reslizumab in eosinophilic asthma, which served as the screening/baseline visit for participation in this open label extension study. The use of systemic corticosteroids for asthma in any of the previous Teva sponsored double blind studies of reslizumab did not exclude patients from this study. The previous Teva studies were C38072/3081 (NCT01270464), C38072/3082 (NCT01287039), and C38072/3083 (NCT01285323)."}, "conditionsModule": {"conditions": ["Eosinophilic Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 1052, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Reslizumab 3.0 mg/kg", "type": "EXPERIMENTAL", "description": "Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months.", "interventionNames": ["Drug: Reslizumab"]}], "interventions": [{"type": "DRUG", "name": "Reslizumab", "description": "Reslizumab (3.0 mg/kg) administered intravenously by infusion every 28 days (\u00b17 days), for approximately 24 months", "armGroupLabels": ["Reslizumab 3.0 mg/kg"], "otherNames": ["Cinquil", "humanized monoclonal antibody", "CEP-38072"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Participants With Treatment-Emergent Adverse Events", "description": "An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.", "timeFrame": "Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observation, which included the 90 day follow-up visit."}, {"measure": "Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Abnormal Lab Values", "description": "Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology, and urinalysis values on any of the during treatment lab analyses.\n\nSignificance criteria:\n\n* Blood urea nitrogen: \\>=10.71 mmol/L\n* Creatinine: \\>=177 \u03bcmol/L\n* Uric acid: M\\>=625, F\\>=506 \u03bcmol/L\n* Aspartate aminotransferase: \\>=3\\*upper limit of normal (ULN). Normal range is 10-43 U/L\n* Alanine aminotransferase: \\>=3\\*ULN. Normal range is 10-40 U/L\n* GGT = gamma-glutamyl transpeptidase: \\>= 3\\*upper limit of normal. Normal range is 5-49 U/L.\n* Total bilirubin: \\>=34.2 \u03bcmol/L\n* White blood cells- low: \\<=3.0\\*10\\^9/L\n* White blood cells-high: \\>=20\\*10\\^9/L\n* Hemoglobin: M\\<=115, F\\<=95 g/dL\n* Hematocrit: M\\<0.37, F\\<0.32 L/L\n* Platelets: \\>=700\\*10\\^9/L\n* Absolute neutrophil count: \\<=1.0\\*10\\^9/L\n* Eosinophils: \\>=10\n* Urinalysis: ketones, blood, glucose, and total protein: \\>=2 unit increase from baseline", "timeFrame": "Weeks 4, 8, 24 and 48"}, {"measure": "Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Vital Signs Values", "description": "Data represents participants with PCS vital sign values during any of the during treatment visits or the follow-up visit.\n\nSignificance criteria\n\n* Sitting heart rate-high: \\>100 and increase of \\>= 30 beats/min (all ages)\n* Sitting heart rate-low: \\<50 and decrease of \\>=30 beats/min\n* Sitting systolic blood pressure (BP)-high: \\>130 and increase of \\>=30 mmHg (ages 12-17)\n* Systolic BP-low: \\<90 and decrease of \\>=30 mmHg (ages \\>=18)\n* Systolic BP-high: \\>160 and increase of \\>=30 mmHg (ages \\>=18)\n* Sitting diastolic BP-low: \\<55 and decrease of \\>=12 mmHg (ages 12-17)\n* Diastolic BP-high: \\>85 and increase of \\>=12 mmHg (ages 12-17)\n* Diastolic BP-low: \\<50 and decrease of \\>=12 mmHg (ages \\>=18)\n* Diastolic BP-high: \\>100 and increase of \\>=12 mmHg (ages \\>=18)\n* Respiration rate: \\>20 and increase of \\>=10 breaths/minute (ages 12-17)\n* Respiration rate: \\>24 and increase of \\>=10 breaths/minute (ages \\>=18)\n* Body temperature-low: \\<96.5\u00b0 Fahrenheit (all ages)\n* Body temp-high: \\>100.5\u00b0 F (all ages)", "timeFrame": "Week 4 to Week 65"}], "secondaryOutcomes": [{"measure": "Forced Expiratory Volume In 1 Second (FEV1) at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint", "description": "FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer.", "timeFrame": "Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint"}, {"measure": "Percent Predicted Forced Expiratory Volume In 1 Second (% Predicted FEV1) at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint", "description": "The percent predicted FEV1 is the ratio of the volume of air expired in the first second of a forced expiration to the patient's predicted FEV based on a similar population without asthma. Percent predicted lung function values were transcribed directly from the lung function report to the CRF, without any calculation by Teva.", "timeFrame": "Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint"}, {"measure": "Forced Vital Capacity (FVC) at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint", "description": "The FVC is the volume of air that can be forcibly blown out after full inspiration, measured in liters.\n\n.", "timeFrame": "Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint"}, {"measure": "Forced Expiratory Flow at 25% to 75% Forced Vital Capacity (FEF 25%-75%) at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint", "description": "The FEF 25%-75% is the force expiratory flow at 25% to 75% of the Forced Vital Capacity (FVC), measured in liters/second\n\n.", "timeFrame": "Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint"}, {"measure": "Average Daily Use of Short-Acting Beta-Agonist (SABA)Therapy at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint", "description": "SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit participants were asked to recall their usage of SABA therapy within the last 3 days of the scheduled visit. If usage was confirmed, the number of puffs used was recorded. For the purpose of summaries, an average daily usage was evaluated by dividing the total number of puffs recorded over 3 days by 3.\n\n.", "timeFrame": "Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint"}, {"measure": "Asthma Symptom Utility Index (ASUI) Score at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint", "description": "The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control.\n\n.", "timeFrame": "Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint"}, {"measure": "Asthma Control Questionnaire (ACQ) at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint", "description": "The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control.", "timeFrame": "Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint"}, {"measure": "Asthma Quality of Life Questionnaire (AQLQ) Total Score at Weeks 24, 48, 72, 96, End of Study and Endpoint", "description": "The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses. Five of the activity questions were \"patient-specific,\" which means that each patient identified and scored 5 activities in which the patient was limited by asthma; these 5 activities were identified at the first visit and retained for all subsequent follow-up visits.", "timeFrame": "Weeks 24, 48, 72, 96, End of Study and Endpoint"}, {"measure": "Participants With a Positive Anti-Reslizumab Antibody Status at Baseline, Weeks 24, 48, 72, 96, End of Study, Endpoint and Overall", "description": "Blood samples were collected for the determination of anti-drug antibody (ADAs) before study drug infusion at baseline and every 24 weeks until end of treatment visit or early withdrawal. Serum samples were analyzed by Teva (Teva Biopharmaceuticals USA, Rockville, Maryland, USA) using a validated homogeneous solution based bridging enzyme linked immune sorbent assay (Mikulsis et al 2011, Qui et al 2010). The analysis of anti-reslizumab antibody in patient serum consists of 3 tiers of assays for screening, confirmation, and titer analysis. If a participant had a treatment-emergent ADA response (ie, ADA positive at any of the postdose time points but negative at the predose time point) or if there was a treatment-boosted ADA response (defined as a greater than 4-fold increase from a positive baseline ADA response (Shankar et at 2014), the participant was classified as overall ADA positive.\n\nPredose samples for the reslizumab-experienced participants came from the previous studies.", "timeFrame": "Baseline, Weeks 24, 48, 72, 96, End of Study, Endpoint and Overall"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent is obtained.\n* Patient must have completed treatment in a previous Cephalon-sponsored double-blind asthma exacerbation study or received at least 2 doses of study drug treatment in a pulmonary function study.\n* The patient must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study period, and willing to return to the clinic for the follow-up evaluation as specified in this protocol.\n* other criteria may apply; please contact the investigator for more information.\n\nExclusion Criteria:\n\n* The patient has a clinically meaningful comorbidity that would interfere with the study schedule or procedures, or compromise the patient's safety.\n* The patient has another confounding underlying lung disorder (eg, chronic obstructive pulmonary disease, pulmonary fibrosis, or lung cancer).\n* The patient is a current smoker.\n* The patient is expected to be poorly compliant with study drug administration, study procedures, or visits.\n* The patient has any aggravating factors that are inadequately controlled (e.g., gastroesophageal reflux disease \\[GERD\\]).\n* Female patients who are pregnant, or nursing, or, if of childbearing potential and not using a medically accepted, effective method of birth control (eg, spermicide, abstinence, intrauterine device \\[IUD\\], or steroidal contraceptive \\[oral, transdermal, implanted, and injected\\] in conjunction with a barrier method) are excluded from this study.\n* The patient has a current infection or disease that may preclude assessment of asthma.\n* other criteria may apply; please contact the investigator for more information.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "75 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Sponsor's Medical Expert, Senior Director - Worldwide Clinical Research", "affiliation": "Cephalon", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Teva Investigational Site 58", "city": "Scottsdale", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.50921, "lon": -111.89903}}, {"facility": "Teva Investigational Site 12", "city": "Anaheim", "state": "California", "country": "United States", "geoPoint": {"lat": 33.83529, "lon": -117.9145}}, {"facility": "Teva Investigational Site 11", "city": "Fountain Valley", "state": "California", "country": "United States", "geoPoint": {"lat": 33.70918, "lon": -117.95367}}, {"facility": "Teva Investigational Site 41", "city": "Fresno", "state": "California", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Teva Investigational Site 59", "city": "Long Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "Teva Investigational Site 43", "city": "Los Angeles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Teva Investigational Site 4", "city": "Orange", "state": "California", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -117.85311}}, {"facility": "Teva Investigational Site 15", "city": "Walnut Creek", "state": "California", "country": "United States", "geoPoint": {"lat": 37.90631, "lon": -122.06496}}, {"facility": "Teva Investigational Site 2", "city": "Colorado Springs", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Teva Investigational Site 34", "city": "Colorado Springs", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Teva Investigational Site 47", "city": "Denver", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Teva Investigational Site 28", "city": "Waterbury", "state": "Connecticut", "country": "United States", "geoPoint": {"lat": 41.55815, "lon": -73.0515}}, {"facility": "Teva Investigational Site 53", "city": "Clearwater", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.96585, "lon": -82.8001}}, {"facility": "Teva Investigational Site 24", "city": "Largo", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.90979, "lon": -82.78842}}, {"facility": "Teva Investigational Site 27", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Teva Investigational Site 55", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Teva Investigational Site 5", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Teva Investigational Site 52", "city": "Orlando", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Teva Investigational Site 19", "city": "Tallahassee", "state": "Florida", "country": "United States", "geoPoint": {"lat": 30.43826, "lon": -84.28073}}, {"facility": "Teva Investigational Site 17", "city": "Trinity", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.18085, "lon": -82.68177}}, {"facility": "Teva Investigational Site 18", "city": "Valrico", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.93789, "lon": -82.23644}}, {"facility": "Teva Investigational Site 25", "city": "Lawrenceville", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.95621, "lon": -83.98796}}, {"facility": "Teva Investigational Site 6", "city": "Lilburn", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.8901, "lon": -84.14297}}, {"facility": "Teva Investigational Site 3", "city": "Savannah", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "Teva Investigational Site 49", "city": "Lexington", "state": "Kentucky", "country": "United States", "geoPoint": {"lat": 37.98869, "lon": -84.47772}}, {"facility": "Teva Investigational Site 46", "city": "Bangor", "state": "Maine", "country": "United States", "geoPoint": {"lat": 44.80118, "lon": -68.77781}}, {"facility": "Teva Investigational Site 40", "city": "St. Louis", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Teva Investigational Site 74", "city": "St. Louis", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Teva Investigational Site 64", "city": "Boys Town", "state": "Nebraska", "country": "United States", "geoPoint": {"lat": 41.26111, "lon": -96.13196}}, {"facility": "Teva Investigational Site 8", "city": "Omaha", "state": "Nebraska", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "Teva Investigational Site 26", "city": "Summit", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 40.71562, "lon": -74.36468}}, {"facility": "Teva Investigational Site 30", "city": "Winston-Salem", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Teva Investigational Site 20", "city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Teva Investigational Site 31", "city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Teva Investigational Site 50", "city": "Oklahoma City", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Teva Investigational Site 1", "city": "Medford", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Teva Investigational Site 66", "city": "Altoona", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.51868, "lon": -78.39474}}, {"facility": "Teva Investigational Site 73", "city": "Lincoln", "state": "Rhode Island", "country": "United States", "geoPoint": {"lat": 41.92111, "lon": -71.435}}, {"facility": "Teva Investigational Site 9", "city": "Providence", "state": "Rhode Island", "country": "United States", "geoPoint": {"lat": 41.82399, "lon": -71.41283}}, {"facility": "Teva Investigational Site 21", "city": "Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Teva Investigational Site 32", "city": "Nashville", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "Teva Investigational Site 63", "city": "Boerne", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.79466, "lon": -98.73197}}, {"facility": "Teva Investigational Site 44", "city": "Dallas", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Teva Investigational Site 69", "city": "El Paso", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "Teva Investigational Site 16", "city": "Fort Worth", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.72541, "lon": -97.32085}}, {"facility": "Teva Investigational Site 14", "city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Teva Investigational Site 45", "city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Teva Investigational Site 33", "city": "Madison", "state": "Wisconsin", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}, {"facility": "Teva Investigational Site 121", "city": "Ciudad Autonoma de Buenos Aire", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Teva Investigational Site 126", "city": "Ciudad Autonoma de Buenos Aire", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Teva Investigational Site 127", "city": "Ciudad Autonoma de Buenos Aire", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Teva Investigational Site 128", "city": "Quilmes-Buenos Aires", "country": "Argentina"}, {"facility": "Teva Investigational Site 123", "city": "Rosario-Santa Fe", "country": "Argentina"}, {"facility": "Teva Investigational Site 125", "city": "Rosario", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Teva Investigational Site 120", "city": "San Miguel de Tucuman - Tucuma", "country": "Argentina"}, {"facility": "Teva Investigational Site 122", "city": "San Miguel de Tucuman - Tucuma", "country": "Argentina"}, {"facility": "Teva Investigational Site 641", "city": "East Bentleigh", "country": "Australia"}, {"facility": "Teva Investigational Site 642", "city": "Frankston", "country": "Australia", "geoPoint": {"lat": -38.14458, "lon": 145.12291}}, {"facility": "Teva Investigational Site 645", "city": "Liverpool", "country": "Australia", "geoPoint": {"lat": -33.90011, "lon": 150.93328}}, {"facility": "Teva Investigational Site 643", "city": "Nedlands", "country": "Australia", "geoPoint": {"lat": -31.98184, "lon": 115.8073}}, {"facility": "Teva Investigational Site 261", "city": "Bruxelles", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Teva Investigational Site 264", "city": "Bruxelles", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Teva Investigational Site 260", "city": "Gent", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "Teva Investigational Site 262", "city": "Jambes", "country": "Belgium", "geoPoint": {"lat": 50.45636, "lon": 4.87166}}, {"facility": "Teva Investigational Site 263", "city": "Li\u00e8ge", "country": "Belgium", "geoPoint": {"lat": 50.63373, "lon": 5.56749}}, {"facility": "Teva Investigational Site 146", "city": "Belo Horizonte", "country": "Brazil", "geoPoint": {"lat": -19.92083, "lon": -43.93778}}, {"facility": "Teva Investigational Site 150", "city": "Florianopolis", "country": "Brazil", "geoPoint": {"lat": -27.59667, "lon": -48.54917}}, {"facility": "Teva Investigational Site 147", "city": "Porto Alegre - RS", "country": "Brazil"}, {"facility": "Teva Investigational Site 143", "city": "Porto Alegre, RS", "country": "Brazil"}, {"facility": "Teva Investigational Site 140", "city": "Porto Alegre", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Teva Investigational Site 144", "city": "Porto Alegre", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Teva Investigational Site 142", "city": "Santo Andr\u00e9, S\u00e3o Paulo", "country": "Brazil"}, {"facility": "Teva Investigational Site 103", "city": "Calgary", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Teva Investigational Site 101", "city": "Montreal", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Teva Investigational Site 104", "city": "Newmarket", "country": "Canada", "geoPoint": {"lat": 44.05011, "lon": -79.46631}}, {"facility": "Teva Investigational Site 105", "city": "Windsor", "country": "Canada", "geoPoint": {"lat": 42.30008, "lon": -83.01654}}, {"facility": "Teva Investigational Site 160", "city": "Rancagua", "country": "Chile", "geoPoint": {"lat": -34.17083, "lon": -70.74444}}, {"facility": "Teva Investigational Site 164", "city": "Santiago", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Teva Investigational Site 161", "city": "Temuco", "country": "Chile", "geoPoint": {"lat": -38.73965, "lon": -72.59842}}, {"facility": "Teva Investigational Site 162", "city": "Valdivia", "country": "Chile", "geoPoint": {"lat": -39.81422, "lon": -73.24589}}, {"facility": "Teva Investigational Site 166", "city": "Valparaiso", "country": "Chile", "geoPoint": {"lat": -33.03932, "lon": -71.62725}}, {"facility": "Teva Investigational Site 185", "city": "Bogota", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Teva Investigational Site 181", "city": "Bogot\u00e1", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Teva Investigational Site 182", "city": "Cali", "country": "Colombia", "geoPoint": {"lat": 3.43722, "lon": -76.5225}}, {"facility": "Teva Investigational Site 180", "city": "Floridablanca", "country": "Colombia", "geoPoint": {"lat": 7.06222, "lon": -73.08644}}, {"facility": "Teva Investigational Site 284", "city": "Breclav", "country": "Czech Republic", "geoPoint": {"lat": 48.75897, "lon": 16.88203}}, {"facility": "Teva Investigational Site 287", "city": "Brno", "country": "Czech Republic", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"facility": "Teva Investigational Site 286", "city": "Liberec", "country": "Czech Republic", "geoPoint": {"lat": 50.76711, "lon": 15.05619}}, {"facility": "Teva Investigational Site 280", "city": "Olomouc", "country": "Czech Republic", "geoPoint": {"lat": 49.59552, "lon": 17.25175}}, {"facility": "Teva Investigational Site 281", "city": "Olomouc", "country": "Czech Republic", "geoPoint": {"lat": 49.59552, "lon": 17.25175}}, {"facility": "Teva Investigational Site 285", "city": "Olomouc", "country": "Czech Republic", "geoPoint": {"lat": 49.59552, "lon": 17.25175}}, {"facility": "Teva Investigational Site 283", "city": "Tabor", "country": "Czech Republic", "geoPoint": {"lat": 49.41441, "lon": 14.6578}}, {"facility": "Teva Investigational Site 300", "city": "Odense", "country": "Denmark", "geoPoint": {"lat": 55.39594, "lon": 10.38831}}, {"facility": "Teva Investigational Site 342", "city": "Marseille", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "Teva Investigational Site 341", "city": "Montpellier", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "Teva Investigational Site 361", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Teva Investigational Site 366", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Teva Investigational Site 371", "city": "Bochum", "country": "Germany", "geoPoint": {"lat": 51.48165, "lon": 7.21648}}, {"facility": "Teva Investigational Site 369", "city": "Frankfurt", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Teva Investigational Site 370", "city": "Hamburg", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Teva Investigational Site 372", "city": "Koblenz", "country": "Germany", "geoPoint": {"lat": 50.35357, "lon": 7.57883}}, {"facility": "Teva Investigational Site 367", "city": "Leipzig", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Teva Investigational Site 363", "city": "Mainz", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Teva Investigational Site 380", "city": "Athens", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"facility": "Teva Investigational Site 401", "city": "Balassagyarmat", "country": "Hungary", "geoPoint": {"lat": 48.07296, "lon": 19.29614}}, {"facility": "Teva Investigational Site 400", "city": "Miskolc", "country": "Hungary", "geoPoint": {"lat": 48.1, "lon": 20.78333}}, {"facility": "Teva Investigational Site 404", "city": "Mosonmagyar\u00f3v\u00e1r", "country": "Hungary", "geoPoint": {"lat": 47.86789, "lon": 17.26994}}, {"facility": "Teva Investigational Site 403", "city": "Sopron", "country": "Hungary", "geoPoint": {"lat": 47.68501, "lon": 16.59049}}, {"facility": "Teva Investigational Site 407", "city": "Szazhalombatta", "country": "Hungary", "geoPoint": {"lat": 47.32579, "lon": 18.92141}}, {"facility": "Teva Investigational Site 402", "city": "Tatab\u00e1nya", "country": "Hungary", "geoPoint": {"lat": 47.58494, "lon": 18.39325}}, {"facility": "Teva Investigational Site 405", "city": "T\u00f6r\u00f6kb\u00e1lint", "country": "Hungary", "geoPoint": {"lat": 47.42931, "lon": 18.91356}}, {"facility": "Teva Investigational Site 423", "city": "Ashkelon", "country": "Israel", "geoPoint": {"lat": 31.66926, "lon": 34.57149}}, {"facility": "Teva Investigational Site 432", "city": "Haifa", "country": "Israel", "geoPoint": {"lat": 32.81841, "lon": 34.9885}}, {"facility": "Teva Investigational Site 425", "city": "Jerusalem", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"facility": "Teva Investigational Site 428", "city": "Jerusalem", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"facility": "Teva Investigational Site 426", "city": "Kfar Saba", "country": "Israel", "geoPoint": {"lat": 32.175, "lon": 34.90694}}, {"facility": "Teva Investigational Site 422", "city": "Petach Tikva", "country": "Israel", "geoPoint": {"lat": 32.08707, "lon": 34.88747}}, {"facility": "Teva Investigational Site 433", "city": "Ramat Gan", "country": "Israel", "geoPoint": {"lat": 32.08227, "lon": 34.81065}}, {"facility": "Teva Investigational Site 421", "city": "Rehovot", "country": "Israel", "geoPoint": {"lat": 31.89421, "lon": 34.81199}}, {"facility": "Teva Investigational Site 420", "city": "Tel-Aviv", "country": "Israel", "geoPoint": {"lat": 32.08088, "lon": 34.78057}}, {"facility": "Teva Investigational Site 682", "city": "Gwangju", "country": "Korea, Republic of", "geoPoint": {"lat": 35.15472, "lon": 126.91556}}, {"facility": "Teva Investigational Site 680", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Teva Investigational Site 681", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Teva Investigational Site 683", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Teva Investigational Site 686", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Teva Investigational Site 685", "city": "Suwon", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "Teva Investigational Site 705", "city": "Batu Caves", "country": "Malaysia", "geoPoint": {"lat": 3.23333, "lon": 101.66667}}, {"facility": "Teva Investigational Site 700", "city": "Kuala Lumpur", "country": "Malaysia", "geoPoint": {"lat": 3.1412, "lon": 101.68653}}, {"facility": "Teva Investigational Site 702", "city": "Kuala Lumpur", "country": "Malaysia", "geoPoint": {"lat": 3.1412, "lon": 101.68653}}, {"facility": "Teva Investigational Site 701", "city": "Penang", "country": "Malaysia"}, {"facility": "Teva Investigational Site 704", "city": "Taiping", "country": "Malaysia", "geoPoint": {"lat": 4.85, "lon": 100.73333}}, {"facility": "Teva Investigational Site 205", "city": "Ciudad De M\u00e9xico", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Teva Investigational Site 203", "city": "Distrito Federal", "country": "Mexico", "geoPoint": {"lat": 16.59, "lon": -93.02694}}, {"facility": "Teva Investigational Site 204", "city": "Guadalajara, JAL", "country": "Mexico"}, {"facility": "Teva Investigational Site 200", "city": "Hermosillo, Sonora", "country": "Mexico"}, {"facility": "Teva Investigational Site 207", "city": "Mexico City", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Teva Investigational Site 209", "city": "Monterrey", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Teva Investigational Site 202", "city": "Tijuana, B.C.", "country": "Mexico"}, {"facility": "Teva Investigational Site 460", "city": "Heerlen", "country": "Netherlands", "geoPoint": {"lat": 50.88365, "lon": 5.98154}}, {"facility": "Teva Investigational Site 723", "city": "Auckland", "country": "New Zealand", "geoPoint": {"lat": -36.84853, "lon": 174.76349}}, {"facility": "Teva Investigational Site 724", "city": "Dunedin", "country": "New Zealand", "geoPoint": {"lat": -45.87416, "lon": 170.50361}}, {"facility": "Teva Investigational Site 727", "city": "Hamilton", "country": "New Zealand", "geoPoint": {"lat": -37.78333, "lon": 175.28333}}, {"facility": "Teva Investigational Site 720", "city": "Tauranga", "country": "New Zealand", "geoPoint": {"lat": -37.68611, "lon": 176.16667}}, {"facility": "Teva Investigational Site 721", "city": "Wellington", "country": "New Zealand", "geoPoint": {"lat": -41.28664, "lon": 174.77557}}, {"facility": "Teva Investigational Site 223", "city": "Cercado de Lima, Lima", "country": "Peru"}, {"facility": "Teva Investigational Site 220", "city": "Lima", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "Teva Investigational Site 221", "city": "Lima", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "Teva Investigational Site 222", "city": "Lima", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "Teva Investigational Site 225", "city": "Lima", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "Teva Investigational Site 226", "city": "Lima", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "Teva Investigational Site 227", "city": "Lima", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "Teva Investigational Site 229", "city": "Lima", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "Teva Investigational Site 742", "city": "Manila", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "Teva Investigational Site 740", "city": "Quezon City", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Teva Investigational Site 741", "city": "Quezon City", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Teva Investigational Site 743", "city": "Quezon City", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Teva Investigational Site 745", "city": "Quezon City", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Teva Investigational Site 507", "city": "Bialystok", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Teva Investigational Site 509", "city": "Bydgoszcz", "country": "Poland", "geoPoint": {"lat": 53.1235, "lon": 18.00762}}, {"facility": "Teva Investigational Site 513", "city": "Gdansk", "country": "Poland", "geoPoint": {"lat": 54.35205, "lon": 18.64637}}, {"facility": "Teva Investigational Site 512", "city": "Lodz", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Teva Investigational Site 505", "city": "Lublin", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "Teva Investigational Site 500", "city": "Ostrow Wielkopolski", "country": "Poland", "geoPoint": {"lat": 51.65501, "lon": 17.80686}}, {"facility": "Teva Investigational Site 511", "city": "Poznan", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Teva Investigational Site 504", "city": "Tarnow", "country": "Poland", "geoPoint": {"lat": 50.01381, "lon": 20.98698}}, {"facility": "Teva Investigational Site 523", "city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Teva Investigational Site 524", "city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Teva Investigational Site 520", "city": "Cluj-Napoca", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "Teva Investigational Site 521", "city": "Iasi", "country": "Romania", "geoPoint": {"lat": 47.16667, "lon": 27.6}}, {"facility": "Teva Investigational Site 522", "city": "Targu Mures", "country": "Romania", "geoPoint": {"lat": 46.54245, "lon": 24.55747}}, {"facility": "Teva Investigational Site 545", "city": "Barnaul", "country": "Russian Federation", "geoPoint": {"lat": 53.36056, "lon": 83.76361}}, {"facility": "Teva Investigational Site 549", "city": "Kemerovo", "country": "Russian Federation", "geoPoint": {"lat": 55.33333, "lon": 86.08333}}, {"facility": "Teva Investigational Site 543", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Teva Investigational Site 544", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Teva Investigational Site 554", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Teva Investigational Site 558", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Teva Investigational Site 559", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Teva Investigational Site 555", "city": "Novosibirsk", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Teva Investigational Site 557", "city": "Novosibirsk", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Teva Investigational Site 541", "city": "St. Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Teva Investigational Site 542", "city": "St. Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Teva Investigational Site 540", "city": "St.Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Teva Investigational Site 552", "city": "Tomsk", "country": "Russian Federation", "geoPoint": {"lat": 56.49771, "lon": 84.97437}}, {"facility": "Teva Investigational Site 546", "city": "Yaroslavl", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"facility": "Teva Investigational Site 563", "city": "Bradejov", "country": "Slovakia"}, {"facility": "Teva Investigational Site 561", "city": "Levice", "country": "Slovakia", "geoPoint": {"lat": 48.21563, "lon": 18.60705}}, {"facility": "Teva Investigational Site 560", "city": "Spisska Nova Ves", "country": "Slovakia", "geoPoint": {"lat": 48.94464, "lon": 20.56153}}, {"facility": "Teva Investigational Site 562", "city": "Topolcany", "country": "Slovakia", "geoPoint": {"lat": 48.56361, "lon": 18.16712}}, {"facility": "Teva Investigational Site 584", "city": "Cape Town", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Teva Investigational Site 586", "city": "Cape Town", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Teva Investigational Site 587", "city": "Centurion", "country": "South Africa", "geoPoint": {"lat": -25.85891, "lon": 28.18577}}, {"facility": "Teva Investigational Site 582", "city": "Durban", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Teva Investigational Site 585", "city": "Durban", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Teva Investigational Site 580", "city": "Johannesburg", "country": "South Africa", "geoPoint": {"lat": -26.20227, "lon": 28.04363}}, {"facility": "Teva Investigational Site 589", "city": "Johannesburg", "country": "South Africa", "geoPoint": {"lat": -26.20227, "lon": 28.04363}}, {"facility": "Teva Investigational Site 583", "city": "Pretoria", "country": "South Africa", "geoPoint": {"lat": -25.74486, "lon": 28.18783}}, {"facility": "Teva Investigational Site 588", "city": "Pretoria", "country": "South Africa", "geoPoint": {"lat": -25.74486, "lon": 28.18783}}, {"facility": "Teva Investigational Site 602", "city": "G\u00f6teborg", "country": "Sweden", "geoPoint": {"lat": 57.70716, "lon": 11.96679}}, {"facility": "Teva Investigational Site 604", "city": "G\u00f6teborg", "country": "Sweden", "geoPoint": {"lat": 57.70716, "lon": 11.96679}}, {"facility": "Teva Investigational Site 603", "city": "Link\u00f6ping", "country": "Sweden", "geoPoint": {"lat": 58.41086, "lon": 15.62157}}, {"facility": "Teva Investigational Site 600", "city": "Lund", "country": "Sweden", "geoPoint": {"lat": 55.70584, "lon": 13.19321}}, {"facility": "Teva Investigational Site 601", "city": "Malm\u00f6", "country": "Sweden", "geoPoint": {"lat": 55.60587, "lon": 13.00073}}, {"facility": "Teva Investigational Site 761", "city": "Taipei", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Teva Investigational Site 763", "city": "Taoyuan", "country": "Taiwan", "geoPoint": {"lat": 24.95233, "lon": 121.20193}}, {"facility": "Teva Investigational Site 780", "city": "Bangkok", "country": "Thailand", "geoPoint": {"lat": 13.75398, "lon": 100.50144}}, {"facility": "Teva Investigational Site 782", "city": "Bangkok", "country": "Thailand", "geoPoint": {"lat": 13.75398, "lon": 100.50144}}, {"facility": "Teva Investigational Site 784", "city": "Nakhon Ratchasima", "country": "Thailand", "geoPoint": {"lat": 14.97066, "lon": 102.10196}}, {"facility": "Teva Investigational Site 621", "city": "Dnipropetrovsk", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "Teva Investigational Site 629", "city": "Donetsk", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"facility": "Teva Investigational Site 630", "city": "Ivano-Frankivsk", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"facility": "Teva Investigational Site 620", "city": "Kharkiv", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Teva Investigational Site 633", "city": "Kharkiv", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Teva Investigational Site 622", "city": "Kyiv", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Teva Investigational Site 623", "city": "Kyiv", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Teva Investigational Site 624", "city": "Kyiv", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Teva Investigational Site 625", "city": "Kyiv", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Teva Investigational Site 626", "city": "Vinnytsya", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"facility": "Teva Investigational Site 631", "city": "Zaporizhzhia", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}, {"facility": "Teva Investigational Site 632", "city": "Zaporizhzhya", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Four hundred-eighty (46%) patients received reslizumab for the first time in Study 3085, having previously received placebo in Studies 3081, 3082, or 3083.", "recruitmentDetails": "A total of 1052 patients with eosinophilic asthma at 201 centers in 30 countries were enrolled in this study.", "groups": [{"id": "FG000", "title": "Previous Placebo-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with placebo in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "FG001", "title": "Previous Reslizumab-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with reslizumab at a variety of dosages in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "481"}, {"groupId": "FG001", "numSubjects": "571"}]}, {"type": "Safety Analysis Set", "achievements": [{"groupId": "FG000", "comment": "One patient was enrolled but not treated.", "numSubjects": "480"}, {"groupId": "FG001", "numSubjects": "571"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Completed study includes completion of the 104 week treatment phase and the 90-day follow-up.", "numSubjects": "15"}, {"groupId": "FG001", "comment": "Completed study includes completion of the 104 week treatment phase and the 90-day follow-up.", "numSubjects": "35"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "466"}, {"groupId": "FG001", "numSubjects": "536"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "11"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "26"}, {"groupId": "FG001", "numSubjects": "32"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Non-compliance to study procedures", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Non-compliance to study medications", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Sponsor closure of study", "reasons": [{"groupId": "FG000", "numSubjects": "420"}, {"groupId": "FG001", "numSubjects": "476"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "6"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Enrolled participants", "groups": [{"id": "BG000", "title": "Previous Placebo-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with placebo in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "BG001", "title": "Previous Reslizumab-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with reslizumab at a variety of dosages in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "481"}, {"groupId": "BG001", "value": "571"}, {"groupId": "BG002", "value": "1052"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "47.4", "spread": "14.53"}, {"groupId": "BG001", "value": "47.1", "spread": "13.58"}, {"groupId": "BG002", "value": "47.2", "spread": "14.02"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "314"}, {"groupId": "BG001", "value": "332"}, {"groupId": "BG002", "value": "646"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "167"}, {"groupId": "BG001", "value": "239"}, {"groupId": "BG002", "value": "406"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "371"}, {"groupId": "BG001", "value": "437"}, {"groupId": "BG002", "value": "808"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "44"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "48"}, {"groupId": "BG002", "value": "87"}]}]}, {"title": "American Indian or Alaskan Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "10"}]}]}, {"title": "Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "57"}, {"groupId": "BG002", "value": "101"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "83"}, {"groupId": "BG001", "value": "118"}, {"groupId": "BG002", "value": "201"}]}]}, {"title": "Non-Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "187"}, {"groupId": "BG001", "value": "178"}, {"groupId": "BG002", "value": "365"}]}]}, {"title": "Non-Hispanic and non-Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "208"}, {"groupId": "BG001", "value": "272"}, {"groupId": "BG002", "value": "480"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}]}]}, {"title": "Weight", "description": "n=466, 555,1021", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "75.4", "spread": "16.67"}, {"groupId": "BG001", "value": "76.5", "spread": "17.85"}, {"groupId": "BG002", "value": "76.0", "spread": "17.32"}]}]}]}, {"title": "Height", "description": "n=463, 555, 1018", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "165.3", "spread": "10.03"}, {"groupId": "BG001", "value": "166.0", "spread": "9.96"}, {"groupId": "BG002", "value": "165.7", "spread": "9.99"}]}]}]}, {"title": "Body Mass Index", "description": "n=463, 555, 1018", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "27.6", "spread": "5.42"}, {"groupId": "BG001", "value": "27.7", "spread": "6.04"}, {"groupId": "BG002", "value": "27.7", "spread": "5.77"}]}]}]}, {"title": "Forced Expiratory Volume in 1 Second (FEV1)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "liters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.096", "spread": "0.7856"}, {"groupId": "BG001", "value": "2.285", "spread": "0.8222"}, {"groupId": "BG002", "value": "2.199", "spread": "0.8108"}]}]}]}, {"title": "% Predicted Expiratory Volume In 1 Second", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of predicted FEV1", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "70.739", "spread": "19.7560"}, {"groupId": "BG001", "value": "75.116", "spread": "19.9404"}, {"groupId": "BG002", "value": "73.115", "spread": "19.9664"}]}]}]}, {"title": "Forced Vital Capacity (FVC)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "liters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3.163", "spread": "1.0357"}, {"groupId": "BG001", "value": "3.366", "spread": "1.0779"}, {"groupId": "BG002", "value": "3.273", "spread": "1.0632"}]}]}]}, {"title": "Forced Expiratory Flow at 25% to 75% Forced Vital Capacity (FEF 25%-75%)", "description": "n= 478, 568, 1046", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "liters/second", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.467", "spread": "0.8890"}, {"groupId": "BG001", "value": "1.634", "spread": "0.9045"}, {"groupId": "BG002", "value": "1.558", "spread": "0.9009"}]}]}]}, {"title": "Asthma Control Questionnaire (ACQ)", "description": "The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control.\n\nn= 480, 571, 1051", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "units on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.832", "spread": "1.0912"}, {"groupId": "BG001", "value": "1.450", "spread": "0.9870"}, {"groupId": "BG002", "value": "1.624", "spread": "1.0527"}]}]}]}, {"title": "Asthma Quality of Life Questionnaire (AQLQ)", "description": "The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses.\n\nn= 476, 569, 1045", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "units on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.170", "spread": "1.2160"}, {"groupId": "BG001", "value": "5.496", "spread": "1.1431"}, {"groupId": "BG002", "value": "5.347", "spread": "1.1875"}]}]}]}, {"title": "Asthma Symptom Utility Index (ASUI)", "description": "The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control.\n\nn= 186, 191, 377", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "units on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.803", "spread": "0.1910"}, {"groupId": "BG001", "value": "0.861", "spread": "0.1479"}, {"groupId": "BG002", "value": "0.832", "spread": "0.1728"}]}]}]}, {"title": "Blood Eosinophil Count", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "10^9 blood eosinophil/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.528", "spread": "0.3792"}, {"groupId": "BG001", "value": "0.078", "spread": "0.1480"}, {"groupId": "BG002", "value": "0.284", "spread": "0.3577"}]}]}]}, {"title": "Used Beta Agonist in Past 3 Days", "description": "Usage of inhaled corticosteroids/long-acting beta-agonists and usage of oral corticosteroids.\n\nn= 480, 571, 1051", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Yes", "categories": [{"measurements": [{"groupId": "BG000", "value": "300"}, {"groupId": "BG001", "value": "297"}, {"groupId": "BG002", "value": "597"}]}]}, {"title": "No", "categories": [{"measurements": [{"groupId": "BG000", "value": "180"}, {"groupId": "BG001", "value": "274"}, {"groupId": "BG002", "value": "454"}]}]}]}, {"title": "Daily average number of puffs in past 3 days", "description": "n= 475, 554, 1029", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "puffs/day", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.130", "spread": "2.4996"}, {"groupId": "BG001", "value": "1.568", "spread": "2.3982"}, {"groupId": "BG002", "value": "1.827", "spread": "2.4604"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Participants With Treatment-Emergent Adverse Events", "description": "An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.", "populationDescription": "Safety analysis set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observation, which included the 90 day follow-up visit.", "groups": [{"id": "OG000", "title": "Previous Placebo-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with placebo in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG001", "title": "Previous Reslizumab-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with reslizumab at a variety of dosages in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG002", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "480"}, {"groupId": "OG001", "value": "571"}, {"groupId": "OG002", "value": "1051"}]}], "classes": [{"title": "At least 1 AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "359"}, {"groupId": "OG001", "value": "385"}, {"groupId": "OG002", "value": "744"}]}]}, {"title": "Severe AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "47"}, {"groupId": "OG002", "value": "78"}]}]}, {"title": "Treatment-related AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "90"}]}]}, {"title": "AE causing patient discontinuation", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "18"}]}]}, {"title": "Serious AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "78"}]}]}, {"title": "Death", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "AE up to follow-up period", "categories": [{"measurements": [{"groupId": "OG000", "value": "344"}, {"groupId": "OG001", "value": "367"}, {"groupId": "OG002", "value": "711"}]}]}, {"title": "AE during follow-up period", "categories": [{"measurements": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "82"}, {"groupId": "OG002", "value": "160"}]}]}]}, {"type": "PRIMARY", "title": "Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Abnormal Lab Values", "description": "Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology, and urinalysis values on any of the during treatment lab analyses.\n\nSignificance criteria:\n\n* Blood urea nitrogen: \\>=10.71 mmol/L\n* Creatinine: \\>=177 \u03bcmol/L\n* Uric acid: M\\>=625, F\\>=506 \u03bcmol/L\n* Aspartate aminotransferase: \\>=3\\*upper limit of normal (ULN). Normal range is 10-43 U/L\n* Alanine aminotransferase: \\>=3\\*ULN. Normal range is 10-40 U/L\n* GGT = gamma-glutamyl transpeptidase: \\>= 3\\*upper limit of normal. Normal range is 5-49 U/L.\n* Total bilirubin: \\>=34.2 \u03bcmol/L\n* White blood cells- low: \\<=3.0\\*10\\^9/L\n* White blood cells-high: \\>=20\\*10\\^9/L\n* Hemoglobin: M\\<=115, F\\<=95 g/dL\n* Hematocrit: M\\<0.37, F\\<0.32 L/L\n* Platelets: \\>=700\\*10\\^9/L\n* Absolute neutrophil count: \\<=1.0\\*10\\^9/L\n* Eosinophils: \\>=10\n* Urinalysis: ketones, blood, glucose, and total protein: \\>=2 unit increase from baseline", "populationDescription": "Safety analysis set, including participants who contributed to the analysis", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Weeks 4, 8, 24 and 48", "groups": [{"id": "OG000", "title": "Previous Placebo-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with placebo in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG001", "title": "Previous Reslizumab-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with reslizumab at a variety of dosages in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG002", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "477"}, {"groupId": "OG001", "value": "567"}, {"groupId": "OG002", "value": "1044"}]}], "classes": [{"title": "Blood urea nitrogen", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "23"}]}]}, {"title": "Creatinine", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "Uric acid", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "13"}]}]}, {"title": "Aspartate aminotransferase", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "11"}]}]}, {"title": "Alanine aminotransferase", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "14"}]}]}, {"title": "GGT", "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "39"}]}]}, {"title": "Total bilirubin", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": "White blood cells- low", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "18"}]}]}, {"title": "White blood cells- high", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Hemoglobin", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "19"}]}]}, {"title": "Hematocrit", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "13"}, {"groupId": "OG002", "value": "26"}]}]}, {"title": "Platelets", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Absolute neutrophil count", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "14"}]}]}, {"title": "Eosinophils", "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "27"}, {"groupId": "OG002", "value": "51"}]}]}, {"title": "Ketones in urine", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "24"}]}]}, {"title": "Blood (hemaglobin) in urine", "categories": [{"measurements": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "55"}, {"groupId": "OG002", "value": "107"}]}]}, {"title": "Glucose in urine", "categories": [{"measurements": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "32"}, {"groupId": "OG002", "value": "54"}]}]}, {"title": "Total protein in urine", "categories": [{"measurements": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "85"}, {"groupId": "OG002", "value": "156"}]}]}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume In 1 Second (FEV1) at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint", "description": "FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer.", "populationDescription": "Safety analysis set of participants with assessments at stated timeframes", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters", "timeFrame": "Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint", "groups": [{"id": "OG000", "title": "Previous Placebo-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with placebo in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG001", "title": "Previous Reslizumab-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with reslizumab at a variety of dosages in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG002", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "480"}, {"groupId": "OG001", "value": "571"}, {"groupId": "OG002", "value": "1051"}]}], "classes": [{"title": "Week 4 (n=457, 552, 1009)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.155", "spread": "0.7636"}, {"groupId": "OG001", "value": "2.277", "spread": "0.7999"}, {"groupId": "OG002", "value": "2.222", "spread": "0.7857"}]}]}, {"title": "Week 8 (n=437, 518, 955)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.162", "spread": "0.7966"}, {"groupId": "OG001", "value": "2.270", "spread": "0.8179"}, {"groupId": "OG002", "value": "2.220", "spread": "0.8096"}]}]}, {"title": "Week 12 (n=426, 499, 925)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.171", "spread": "0.7690"}, {"groupId": "OG001", "value": "2.267", "spread": "0.8114"}, {"groupId": "OG002", "value": "2.223", "spread": "0.7932"}]}]}, {"title": "Week 16 (n=418, 488, 906)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.169", "spread": "0.7761"}, {"groupId": "OG001", "value": "2.267", "spread": "0.8101"}, {"groupId": "OG002", "value": "2.222", "spread": "0.7957"}]}]}, {"title": "Week 24 (n=386, 458, 844)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.188", "spread": "0.7966"}, {"groupId": "OG001", "value": "2.289", "spread": "0.8032"}, {"groupId": "OG002", "value": "2.243", "spread": "0.8013"}]}]}, {"title": "Week 36 (n=291, 354, 645)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.234", "spread": "0.8240"}, {"groupId": "OG001", "value": "2.278", "spread": "0.8133"}, {"groupId": "OG002", "value": "2.258", "spread": "0.8178"}]}]}, {"title": "Week 48 (n=198, 250, 448)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.167", "spread": "0.7905"}, {"groupId": "OG001", "value": "2.336", "spread": "0.8189"}, {"groupId": "OG002", "value": "2.261", "spread": "0.8099"}]}]}, {"title": "Week 60 (n=101, 143, 244)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.234", "spread": "0.9214"}, {"groupId": "OG001", "value": "2.360", "spread": "0.8292"}, {"groupId": "OG002", "value": "2.308", "spread": "0.8689"}]}]}, {"title": "Week 72 (n=56, 105, 161)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.424", "spread": "0.9093"}, {"groupId": "OG001", "value": "2.367", "spread": "0.8150"}, {"groupId": "OG002", "value": "2.387", "spread": "0.8466"}]}]}, {"title": "Week 84 (n=45, 88, 133)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.496", "spread": "0.8496"}, {"groupId": "OG001", "value": "2.384", "spread": "0.8411"}, {"groupId": "OG002", "value": "2.422", "spread": "0.8425"}]}]}, {"title": "Week 96 (n=23, 46, 69)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.748", "spread": "0.8963"}, {"groupId": "OG001", "value": "2.383", "spread": "0.7737"}, {"groupId": "OG002", "value": "2.505", "spread": "0.8283"}]}]}, {"title": "End of study (n=28, 54, 82)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.505", "spread": "0.9386"}, {"groupId": "OG001", "value": "2.237", "spread": "0.8736"}, {"groupId": "OG002", "value": "2.329", "spread": "0.8997"}]}]}, {"title": "Endpoint (n=478, 569, 1047)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.174", "spread": "0.7798"}, {"groupId": "OG001", "value": "2.273", "spread": "0.8127"}, {"groupId": "OG002", "value": "2.228", "spread": "0.7989"}]}]}]}, {"type": "SECONDARY", "title": "Percent Predicted Forced Expiratory Volume In 1 Second (% Predicted FEV1) at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint", "description": "The percent predicted FEV1 is the ratio of the volume of air expired in the first second of a forced expiration to the patient's predicted FEV based on a similar population without asthma. Percent predicted lung function values were transcribed directly from the lung function report to the CRF, without any calculation by Teva.", "populationDescription": "Safety analysis set of participants with assessments at stated timeframes", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of predicted FEV1", "timeFrame": "Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint", "groups": [{"id": "OG000", "title": "Previous Placebo-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with placebo in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG001", "title": "Previous Reslizumab-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with reslizumab at a variety of dosages in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG002", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "480"}, {"groupId": "OG001", "value": "571"}, {"groupId": "OG002", "value": "1051"}]}], "classes": [{"title": "Week 4 (n=457, 552, 1009)", "categories": [{"measurements": [{"groupId": "OG000", "value": "73.295", "spread": "19.7933"}, {"groupId": "OG001", "value": "74.808", "spread": "19.1560"}, {"groupId": "OG002", "value": "74.123", "spread": "19.4521"}]}]}, {"title": "Week 8 (n=437, 518, 955)", "categories": [{"measurements": [{"groupId": "OG000", "value": "73.056", "spread": "19.9848"}, {"groupId": "OG001", "value": "74.765", "spread": "20.3570"}, {"groupId": "OG002", "value": "73.983", "spread": "20.1949"}]}]}, {"title": "Week 12 (n=426, 499, 925)", "categories": [{"measurements": [{"groupId": "OG000", "value": "73.797", "spread": "19.2586"}, {"groupId": "OG001", "value": "74.690", "spread": "19.8973"}, {"groupId": "OG002", "value": "74.279", "spread": "19.6002"}]}]}, {"title": "Week 16 (n=418, 488, 906)", "categories": [{"measurements": [{"groupId": "OG000", "value": "73.797", "spread": "19.5962"}, {"groupId": "OG001", "value": "74.668", "spread": "20.2025"}, {"groupId": "OG002", "value": "74.266", "spread": "19.9188"}]}]}, {"title": "Week 24 (n=386, 458, 844)", "categories": [{"measurements": [{"groupId": "OG000", "value": "74.284", "spread": "19.5601"}, {"groupId": "OG001", "value": "75.208", "spread": "19.9621"}, {"groupId": "OG002", "value": "74.785", "spread": "19.7729"}]}]}, {"title": "Week 36 (n=291, 354, 645)", "categories": [{"measurements": [{"groupId": "OG000", "value": "74.805", "spread": "20.5634"}, {"groupId": "OG001", "value": "75.487", "spread": "20.4589"}, {"groupId": "OG002", "value": "75.179", "spread": "20.4930"}]}]}, {"title": "Week 48 (n=198, 250, 448)", "categories": [{"measurements": [{"groupId": "OG000", "value": "73.654", "spread": "19.9535"}, {"groupId": "OG001", "value": "76.627", "spread": "19.8890"}, {"groupId": "OG002", "value": "75.313", "spread": "19.9500"}]}]}, {"title": "Week 60 (n=101, 143, 244)", "categories": [{"measurements": [{"groupId": "OG000", "value": "74.511", "spread": "22.5211"}, {"groupId": "OG001", "value": "76.613", "spread": "20.2416"}, {"groupId": "OG002", "value": "75.743", "spread": "21.1950"}]}]}, {"title": "Week 72 (n=56, 105, 161)", "categories": [{"measurements": [{"groupId": "OG000", "value": "76.856", "spread": "20.1821"}, {"groupId": "OG001", "value": "76.812", "spread": "17.1937"}, {"groupId": "OG002", "value": "76.827", "spread": "18.2256"}]}]}, {"title": "Week 84 (n=45, 88, 133)", "categories": [{"measurements": [{"groupId": "OG000", "value": "79.017", "spread": "18.5149"}, {"groupId": "OG001", "value": "77.945", "spread": "18.4383"}, {"groupId": "OG002", "value": "78.308", "spread": "18.4011"}]}]}, {"title": "Week 96 (n=23, 46, 69)", "categories": [{"measurements": [{"groupId": "OG000", "value": "83.245", "spread": "14.9074"}, {"groupId": "OG001", "value": "76.746", "spread": "16.2345"}, {"groupId": "OG002", "value": "78.912", "spread": "15.9949"}]}]}, {"title": "End of study (n=28, 54, 82)", "categories": [{"measurements": [{"groupId": "OG000", "value": "79.672", "spread": "18.6997"}, {"groupId": "OG001", "value": "70.633", "spread": "20.2554"}, {"groupId": "OG002", "value": "73.719", "spread": "20.0902"}]}]}, {"title": "Endpoint (n=478, 569, 1047)", "categories": [{"measurements": [{"groupId": "OG000", "value": "74.195", "spread": "19.8134"}, {"groupId": "OG001", "value": "75.107", "spread": "19.8530"}, {"groupId": "OG002", "value": "74.690", "spread": "19.8307"}]}]}]}, {"type": "SECONDARY", "title": "Forced Vital Capacity (FVC) at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint", "description": "The FVC is the volume of air that can be forcibly blown out after full inspiration, measured in liters.\n\n.", "populationDescription": "Safety analysis set of participants with assessments at stated timeframes", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters", "timeFrame": "Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint", "groups": [{"id": "OG000", "title": "Previous Placebo-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with placebo in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG001", "title": "Previous Reslizumab-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with reslizumab at a variety of dosages in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG002", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "480"}, {"groupId": "OG001", "value": "571"}, {"groupId": "OG002", "value": "1051"}]}], "classes": [{"title": "Week 4 (n=457, 552, 1009)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.222", "spread": "0.9929"}, {"groupId": "OG001", "value": "3.372", "spread": "1.0619"}, {"groupId": "OG002", "value": "3.304", "spread": "1.0334"}]}]}, {"title": "Week 8 (n=437, 518, 955)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.226", "spread": "1.0228"}, {"groupId": "OG001", "value": "3.358", "spread": "1.0836"}, {"groupId": "OG002", "value": "3.297", "spread": "1.0577"}]}]}, {"title": "Week 12 (n=426, 499, 925)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.238", "spread": "0.9788"}, {"groupId": "OG001", "value": "3.339", "spread": "1.0584"}, {"groupId": "OG002", "value": "3.292", "spread": "1.0232"}]}]}, {"title": "Week 16 (n=418, 488, 906)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.238", "spread": "0.9949"}, {"groupId": "OG001", "value": "3.349", "spread": "1.0835"}, {"groupId": "OG002", "value": "3.298", "spread": "1.0444"}]}]}, {"title": "Week 24 (n=386, 458, 844)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.233", "spread": "1.0095"}, {"groupId": "OG001", "value": "3.369", "spread": "1.0709"}, {"groupId": "OG002", "value": "3.307", "spread": "1.0449"}]}]}, {"title": "Week 36 (n=291, 353, 644)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.324", "spread": "1.0571"}, {"groupId": "OG001", "value": "3.346", "spread": "1.0416"}, {"groupId": "OG002", "value": "3.336", "spread": "1.0479"}]}]}, {"title": "Week 48 (n=198, 250, 448)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.229", "spread": "1.0334"}, {"groupId": "OG001", "value": "3.414", "spread": "1.0348"}, {"groupId": "OG002", "value": "3.332", "spread": "1.0371"}]}]}, {"title": "Week 60 (n=101, 143, 244)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.323", "spread": "1.1874"}, {"groupId": "OG001", "value": "3.422", "spread": "1.0428"}, {"groupId": "OG002", "value": "3.381", "spread": "1.1037"}]}]}, {"title": "Week 72 (n=56, 105, 161)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.500", "spread": "1.1839"}, {"groupId": "OG001", "value": "3.398", "spread": "1.0795"}, {"groupId": "OG002", "value": "3.434", "spread": "1.1143"}]}]}, {"title": "Week 84 (n=45, 88, 133)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.606", "spread": "1.1403"}, {"groupId": "OG001", "value": "3.406", "spread": "1.1535"}, {"groupId": "OG002", "value": "3.474", "spread": "1.1487"}]}]}, {"title": "Week 96 (n=23, 46, 69)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.849", "spread": "1.2342"}, {"groupId": "OG001", "value": "3.381", "spread": "1.1145"}, {"groupId": "OG002", "value": "3.537", "spread": "1.1680"}]}]}, {"title": "End of study (n=28, 54, 82)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.524", "spread": "1.1842"}, {"groupId": "OG001", "value": "3.321", "spread": "1.2443"}, {"groupId": "OG002", "value": "3.390", "spread": "1.2206"}]}]}, {"title": "Endpoint (n=478, 569, 1047)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.250", "spread": "1.0194"}, {"groupId": "OG001", "value": "3.355", "spread": "1.0675"}, {"groupId": "OG002", "value": "3.307", "spread": "1.0466"}]}]}]}, {"type": "SECONDARY", "title": "Forced Expiratory Flow at 25% to 75% Forced Vital Capacity (FEF 25%-75%) at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint", "description": "The FEF 25%-75% is the force expiratory flow at 25% to 75% of the Forced Vital Capacity (FVC), measured in liters/second\n\n.", "populationDescription": "Safety analysis set of participants with assessments at stated timeframes", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters/second", "timeFrame": "Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint", "groups": [{"id": "OG000", "title": "Previous Placebo-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with placebo in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG001", "title": "Previous Reslizumab-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with reslizumab at a variety of dosages in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG002", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "480"}, {"groupId": "OG001", "value": "571"}, {"groupId": "OG002", "value": "1051"}]}], "classes": [{"title": "Week 4 (n=446, 545, 991)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.558", "spread": "0.9363"}, {"groupId": "OG001", "value": "1.614", "spread": "0.9055"}, {"groupId": "OG002", "value": "1.589", "spread": "0.9195"}]}]}, {"title": "Week 8 (n=429, 513, 942)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.546", "spread": "0.9279"}, {"groupId": "OG001", "value": "1.618", "spread": "0.9255"}, {"groupId": "OG002", "value": "1.585", "spread": "0.9268"}]}]}, {"title": "Week 12 (n=418, 494, 912)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.587", "spread": "0.9833"}, {"groupId": "OG001", "value": "1.624", "spread": "0.9367"}, {"groupId": "OG002", "value": "1.607", "spread": "0.9580"}]}]}, {"title": "Week 16 (n=408, 483, 891)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.561", "spread": "0.9427"}, {"groupId": "OG001", "value": "1.620", "spread": "0.9068"}, {"groupId": "OG002", "value": "1.593", "spread": "0.9234"}]}]}, {"title": "Week 24 (n=377, 453, 830)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.619", "spread": "0.9967"}, {"groupId": "OG001", "value": "1.637", "spread": "0.9227"}, {"groupId": "OG002", "value": "1.629", "spread": "0.9565"}]}]}, {"title": "Week 36 (n=285, 349, 634)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.642", "spread": "1.1087"}, {"groupId": "OG001", "value": "1.650", "spread": "0.9193"}, {"groupId": "OG002", "value": "1.646", "spread": "1.0080"}]}]}, {"title": "Week 48 (n=191, 249, 440)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.628", "spread": "1.0408"}, {"groupId": "OG001", "value": "1.691", "spread": "0.9450"}, {"groupId": "OG002", "value": "1.664", "spread": "0.9871"}]}]}, {"title": "Week 60 (n=99, 143, 242)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.605", "spread": "1.0869"}, {"groupId": "OG001", "value": "1.791", "spread": "1.1508"}, {"groupId": "OG002", "value": "1.715", "spread": "1.1265"}]}]}, {"title": "Week 72 (n=56, 105, 161)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.810", "spread": "1.0239"}, {"groupId": "OG001", "value": "1.766", "spread": "1.0341"}, {"groupId": "OG002", "value": "1.781", "spread": "1.0276"}]}]}, {"title": "Week 84 (n=45, 88, 133)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.848", "spread": "0.9047"}, {"groupId": "OG001", "value": "1.892", "spread": "1.1499"}, {"groupId": "OG002", "value": "1.877", "spread": "1.0700"}]}]}, {"title": "Week 96 (n=23, 46, 69)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.120", "spread": "1.0597"}, {"groupId": "OG001", "value": "1.942", "spread": "1.0453"}, {"groupId": "OG002", "value": "2.001", "spread": "1.0457"}]}]}, {"title": "End of study (n=28, 54, 82)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.939", "spread": "1.1105"}, {"groupId": "OG001", "value": "1.639", "spread": "0.9079"}, {"groupId": "OG002", "value": "1.741", "spread": "0.9854"}]}]}, {"title": "Endpoint (n=468, 563, 1031)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.546", "spread": "0.9041"}, {"groupId": "OG001", "value": "1.629", "spread": "0.9300"}, {"groupId": "OG002", "value": "1.592", "spread": "0.9188"}]}]}]}, {"type": "SECONDARY", "title": "Average Daily Use of Short-Acting Beta-Agonist (SABA)Therapy at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint", "description": "SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit participants were asked to recall their usage of SABA therapy within the last 3 days of the scheduled visit. If usage was confirmed, the number of puffs used was recorded. For the purpose of summaries, an average daily usage was evaluated by dividing the total number of puffs recorded over 3 days by 3.\n\n.", "populationDescription": "Safety analysis set of participants with assessments at stated timeframes", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "# puffs/day", "timeFrame": "Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint", "groups": [{"id": "OG000", "title": "Previous Placebo-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with placebo in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG001", "title": "Previous Reslizumab-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with reslizumab at a variety of dosages in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG002", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "480"}, {"groupId": "OG001", "value": "571"}, {"groupId": "OG002", "value": "1051"}]}], "classes": [{"title": "Week 4 (n=276, 323, 599)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.5", "spread": "2.42"}, {"groupId": "OG001", "value": "2.4", "spread": "2.45"}, {"groupId": "OG002", "value": "2.5", "spread": "2.43"}]}]}, {"title": "Week 8 (n=258, 302, 560)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.4", "spread": "2.28"}, {"groupId": "OG001", "value": "2.4", "spread": "2.62"}, {"groupId": "OG002", "value": "2.4", "spread": "2.46"}]}]}, {"title": "Week 12 (n=251, 278, 529)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.6", "spread": "2.07"}, {"groupId": "OG001", "value": "2.4", "spread": "2.50"}, {"groupId": "OG002", "value": "2.5", "spread": "2.30"}]}]}, {"title": "Week 16 (n=244, 261, 505)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.5", "spread": "2.30"}, {"groupId": "OG001", "value": "2.2", "spread": "2.29"}, {"groupId": "OG002", "value": "2.4", "spread": "2.30"}]}]}, {"title": "Week 24 (n=211, 243, 454)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.6", "spread": "2.55"}, {"groupId": "OG001", "value": "2.3", "spread": "2.46"}, {"groupId": "OG002", "value": "2.4", "spread": "2.51"}]}]}, {"title": "Week 36 (n=160, 174, 334)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.4", "spread": "2.27"}, {"groupId": "OG001", "value": "2.3", "spread": "2.64"}, {"groupId": "OG002", "value": "2.3", "spread": "2.47"}]}]}, {"title": "Week 48 (n=111, 121, 232)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.2", "spread": "2.28"}, {"groupId": "OG001", "value": "2.4", "spread": "2.54"}, {"groupId": "OG002", "value": "2.3", "spread": "2.42"}]}]}, {"title": "Week 60 (n=50, 64, 114)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.1", "spread": "2.19"}, {"groupId": "OG001", "value": "2.5", "spread": "3.30"}, {"groupId": "OG002", "value": "2.3", "spread": "2.86"}]}]}, {"title": "Week 72 (n=29, 47, 76)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.1", "spread": "2.19"}, {"groupId": "OG001", "value": "1.8", "spread": "1.88"}, {"groupId": "OG002", "value": "1.9", "spread": "1.99"}]}]}, {"title": "Week 84 (n=19, 35, 54)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "spread": "1.57"}, {"groupId": "OG001", "value": "2.4", "spread": "2.38"}, {"groupId": "OG002", "value": "2.2", "spread": "2.12"}]}]}, {"title": "Week 96 (n=14, 26, 40)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.8", "spread": "1.41"}, {"groupId": "OG001", "value": "1.7", "spread": "1.57"}, {"groupId": "OG002", "value": "1.8", "spread": "1.50"}]}]}, {"title": "End of study (n=16, 23, 39)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.1", "spread": "1.76"}, {"groupId": "OG001", "value": "2.7", "spread": "1.99"}, {"groupId": "OG002", "value": "2.4", "spread": "1.90"}]}]}, {"title": "Endpoint (n=390, 453, 843)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.2", "spread": "2.20"}, {"groupId": "OG001", "value": "2.2", "spread": "4.09"}, {"groupId": "OG002", "value": "2.2", "spread": "3.35"}]}]}]}, {"type": "PRIMARY", "title": "Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Vital Signs Values", "description": "Data represents participants with PCS vital sign values during any of the during treatment visits or the follow-up visit.\n\nSignificance criteria\n\n* Sitting heart rate-high: \\>100 and increase of \\>= 30 beats/min (all ages)\n* Sitting heart rate-low: \\<50 and decrease of \\>=30 beats/min\n* Sitting systolic blood pressure (BP)-high: \\>130 and increase of \\>=30 mmHg (ages 12-17)\n* Systolic BP-low: \\<90 and decrease of \\>=30 mmHg (ages \\>=18)\n* Systolic BP-high: \\>160 and increase of \\>=30 mmHg (ages \\>=18)\n* Sitting diastolic BP-low: \\<55 and decrease of \\>=12 mmHg (ages 12-17)\n* Diastolic BP-high: \\>85 and increase of \\>=12 mmHg (ages 12-17)\n* Diastolic BP-low: \\<50 and decrease of \\>=12 mmHg (ages \\>=18)\n* Diastolic BP-high: \\>100 and increase of \\>=12 mmHg (ages \\>=18)\n* Respiration rate: \\>20 and increase of \\>=10 breaths/minute (ages 12-17)\n* Respiration rate: \\>24 and increase of \\>=10 breaths/minute (ages \\>=18)\n* Body temperature-low: \\<96.5\u00b0 Fahrenheit (all ages)\n* Body temp-high: \\>100.5\u00b0 F (all ages)", "populationDescription": "Safety analysis set, including participants who contributed to the analysis", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 4 to Week 65", "groups": [{"id": "OG000", "title": "Previous Placebo-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with placebo in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG001", "title": "Previous Reslizumab-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with reslizumab at a variety of dosages in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG002", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "478"}, {"groupId": "OG001", "value": "569"}, {"groupId": "OG002", "value": "1047"}]}], "classes": [{"title": "Heart rate - high (ages 12-17)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Heart rate - low (ages >=18)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Heart rate - high (ages >=18)", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "16"}]}]}, {"title": "Systolic BP - high (ages 12-17)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Systolic BP - low (ages >=18)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Systolic BP - high (ages >=18)", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "16"}]}]}, {"title": "Diastolic BP - low (ages 12-17)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Diastolic BP - high (ages 12-17)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Diastolic BP - low (ages >=18)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": "Diastolic - high (ages >=18)", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "25"}]}]}, {"title": "Respiration rate - high (ages 12-17)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Respiration rate - high (ages >=18)", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "8"}]}]}, {"title": "Body temperature - low (ages 12-17)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": "Body temperature - high (ages 12-17)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Body temperature - low (ages >=18)", "categories": [{"measurements": [{"groupId": "OG000", "value": "102"}, {"groupId": "OG001", "value": "121"}, {"groupId": "OG002", "value": "223"}]}]}, {"title": "Body temperature - high (ages >=18)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "4"}]}]}]}, {"type": "SECONDARY", "title": "Asthma Symptom Utility Index (ASUI) Score at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint", "description": "The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control.\n\n.", "populationDescription": "Safety analysis set of participants with assessments at stated timeframes", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint", "groups": [{"id": "OG000", "title": "Previous Placebo-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with placebo in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG001", "title": "Previous Reslizumab-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with reslizumab at a variety of dosages in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG002", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "480"}, {"groupId": "OG001", "value": "571"}, {"groupId": "OG002", "value": "1051"}]}], "classes": [{"title": "Week 4 (n=456, 552, 1008)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.831", "spread": "0.1829"}, {"groupId": "OG001", "value": "0.844", "spread": "0.1631"}, {"groupId": "OG002", "value": "0.838", "spread": "0.1724"}]}]}, {"title": "Week 8 (n=436, 514, 950)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.843", "spread": "0.1663"}, {"groupId": "OG001", "value": "0.851", "spread": "0.1596"}, {"groupId": "OG002", "value": "0.847", "spread": "0.1626"}]}]}, {"title": "Week 12 (n=426, 500, 926)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.839", "spread": "0.1752"}, {"groupId": "OG001", "value": "0.854", "spread": "0.1578"}, {"groupId": "OG002", "value": "0.847", "spread": "0.1661"}]}]}, {"title": "Week 16 (n=416, 486, 902)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.845", "spread": "0.1690"}, {"groupId": "OG001", "value": "0.856", "spread": "0.1659"}, {"groupId": "OG002", "value": "0.851", "spread": "0.1673"}]}]}, {"title": "Week 24 (n=386, 458, 844)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.844", "spread": "0.1720"}, {"groupId": "OG001", "value": "0.859", "spread": "0.1602"}, {"groupId": "OG002", "value": "0.852", "spread": "0.1658"}]}]}, {"title": "Week 36 (n=291, 354, 645)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.844", "spread": "0.1821"}, {"groupId": "OG001", "value": "0.867", "spread": "0.1536"}, {"groupId": "OG002", "value": "0.857", "spread": "0.1673"}]}]}, {"title": "Week 48 (n=198, 251, 449)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.851", "spread": "0.1699"}, {"groupId": "OG001", "value": "0.856", "spread": "0.1705"}, {"groupId": "OG002", "value": "0.854", "spread": "0.1701"}]}]}, {"title": "Week 60 (n=100, 146, 246)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.869", "spread": "0.1573"}, {"groupId": "OG001", "value": "0.865", "spread": "0.1513"}, {"groupId": "OG002", "value": "0.866", "spread": "0.1534"}]}]}, {"title": "Week 72 (n=56, 105, 161)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.876", "spread": "0.1346"}, {"groupId": "OG001", "value": "0.858", "spread": "0.1509"}, {"groupId": "OG002", "value": "0.865", "spread": "0.1453"}]}]}, {"title": "Week 84 (n=45, 87, 132)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.884", "spread": "0.1460"}, {"groupId": "OG001", "value": "0.868", "spread": "0.1541"}, {"groupId": "OG002", "value": "0.873", "spread": "0.1510"}]}]}, {"title": "Week 96 (n=23, 46, 69)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.822", "spread": "0.2036"}, {"groupId": "OG001", "value": "0.836", "spread": "0.1729"}, {"groupId": "OG002", "value": "0.832", "spread": "0.1823"}]}]}, {"title": "End of study (n=28, 55, 83)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.877", "spread": "0.0979"}, {"groupId": "OG001", "value": "0.840", "spread": "0.2053"}, {"groupId": "OG002", "value": "0.853", "spread": "0.1767"}]}]}, {"title": "Endpoint (n=478, 569, 1047)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.843", "spread": "0.1679"}, {"groupId": "OG001", "value": "0.850", "spread": "0.1661"}, {"groupId": "OG002", "value": "0.847", "spread": "0.1669"}]}]}]}, {"type": "SECONDARY", "title": "Asthma Control Questionnaire (ACQ) at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint", "description": "The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control.", "populationDescription": "Safety analysis set of participants with assessments at stated timeframes", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint", "groups": [{"id": "OG000", "title": "Previous Placebo-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with placebo in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG001", "title": "Previous Reslizumab-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with reslizumab at a variety of dosages in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG002", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "480"}, {"groupId": "OG001", "value": "571"}, {"groupId": "OG002", "value": "1051"}]}], "classes": [{"title": "Week 4 (n=456, 552, 1008)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.546", "spread": "1.0154"}, {"groupId": "OG001", "value": "1.429", "spread": "0.9573"}, {"groupId": "OG002", "value": "1.482", "spread": "0.9852"}]}]}, {"title": "Week 8 (n=437, 517, 954)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.446", "spread": "0.9805"}, {"groupId": "OG001", "value": "1.392", "spread": "0.9729"}, {"groupId": "OG002", "value": "1.417", "spread": "0.9762"}]}]}, {"title": "Week 12 (n=426, 500, 926)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.459", "spread": "1.0004"}, {"groupId": "OG001", "value": "1.360", "spread": "0.9320"}, {"groupId": "OG002", "value": "1.405", "spread": "0.9648"}]}]}, {"title": "Week 16 (n=416, 487, 903)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.444", "spread": "1.0016"}, {"groupId": "OG001", "value": "1.305", "spread": "0.9299"}, {"groupId": "OG002", "value": "1.369", "spread": "0.9655"}]}]}, {"title": "Week 24 (n=386, 458, 844)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.436", "spread": "1.0135"}, {"groupId": "OG001", "value": "1.299", "spread": "0.9497"}, {"groupId": "OG002", "value": "1.362", "spread": "0.9812"}]}]}, {"title": "Week 36 (n=291, 353, 644)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.425", "spread": "1.0189"}, {"groupId": "OG001", "value": "1.282", "spread": "0.9331"}, {"groupId": "OG002", "value": "1.347", "spread": "0.9746"}]}]}, {"title": "Week 48 (n=198, 250, 448)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.408", "spread": "0.9699"}, {"groupId": "OG001", "value": "1.297", "spread": "0.9810"}, {"groupId": "OG002", "value": "1.346", "spread": "0.9766"}]}]}, {"title": "Week 60 (n=100, 143, 243)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.284", "spread": "0.9739"}, {"groupId": "OG001", "value": "1.297", "spread": "0.9432"}, {"groupId": "OG002", "value": "1.292", "spread": "0.9540"}]}]}, {"title": "Week 72 (n=56, 105, 161)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.283", "spread": "0.9176"}, {"groupId": "OG001", "value": "1.231", "spread": "0.8295"}, {"groupId": "OG002", "value": "1.249", "spread": "0.8587"}]}]}, {"title": "Week 84 (n=45, 87, 132)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.143", "spread": "0.9020"}, {"groupId": "OG001", "value": "1.209", "spread": "0.9186"}, {"groupId": "OG002", "value": "1.186", "spread": "0.9100"}]}]}, {"title": "Week 96 (n=23, 46, 69)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.323", "spread": "0.9862"}, {"groupId": "OG001", "value": "1.391", "spread": "0.9559"}, {"groupId": "OG002", "value": "1.369", "spread": "0.9594"}]}]}, {"title": "End of study (n=28, 54, 82)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.061", "spread": "0.7653"}, {"groupId": "OG001", "value": "1.437", "spread": "0.9750"}, {"groupId": "OG002", "value": "1.308", "spread": "0.9216"}]}]}, {"title": "Endpoint (n=478, 569, 1047)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.450", "spread": "0.9901"}, {"groupId": "OG001", "value": "1.389", "spread": "0.9637"}, {"groupId": "OG002", "value": "1.417", "spread": "0.9759"}]}]}]}, {"type": "SECONDARY", "title": "Asthma Quality of Life Questionnaire (AQLQ) Total Score at Weeks 24, 48, 72, 96, End of Study and Endpoint", "description": "The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses. Five of the activity questions were \"patient-specific,\" which means that each patient identified and scored 5 activities in which the patient was limited by asthma; these 5 activities were identified at the first visit and retained for all subsequent follow-up visits.", "populationDescription": "Safety analysis set of participants with assessments at stated timeframes", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Weeks 24, 48, 72, 96, End of Study and Endpoint", "groups": [{"id": "OG000", "title": "Previous Placebo-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with placebo in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG001", "title": "Previous Reslizumab-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with reslizumab at a variety of dosages in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG002", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "480"}, {"groupId": "OG001", "value": "571"}, {"groupId": "OG002", "value": "1051"}]}], "classes": [{"title": "Week 24 (n=382, 452, 834)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.551", "spread": "1.1558"}, {"groupId": "OG001", "value": "5.691", "spread": "1.0651"}, {"groupId": "OG002", "value": "5.627", "spread": "1.1091"}]}]}, {"title": "Week 48 (n=193, 249, 442)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.602", "spread": "1.1180"}, {"groupId": "OG001", "value": "5.725", "spread": "1.0818"}, {"groupId": "OG002", "value": "5.672", "spread": "1.0982"}]}]}, {"title": "Week 72 (n=56, 106, 162)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.808", "spread": "1.0002"}, {"groupId": "OG001", "value": "5.809", "spread": "1.0235"}, {"groupId": "OG002", "value": "5.809", "spread": "1.0124"}]}]}, {"title": "Week 96 (n=23, 46, 69)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.585", "spread": "1.1422"}, {"groupId": "OG001", "value": "5.809", "spread": "1.1340"}, {"groupId": "OG002", "value": "5.734", "spread": "1.1333"}]}]}, {"title": "End of study (n=28, 55, 83)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.956", "spread": "0.9431"}, {"groupId": "OG001", "value": "5.765", "spread": "1.2361"}, {"groupId": "OG002", "value": "5.829", "spread": "1.1434"}]}]}, {"title": "Endpoint (n=472, 558, 1030)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.535", "spread": "1.1690"}, {"groupId": "OG001", "value": "5.631", "spread": "1.1334"}, {"groupId": "OG002", "value": "5.587", "spread": "1.1503"}]}]}]}, {"type": "SECONDARY", "title": "Participants With a Positive Anti-Reslizumab Antibody Status at Baseline, Weeks 24, 48, 72, 96, End of Study, Endpoint and Overall", "description": "Blood samples were collected for the determination of anti-drug antibody (ADAs) before study drug infusion at baseline and every 24 weeks until end of treatment visit or early withdrawal. Serum samples were analyzed by Teva (Teva Biopharmaceuticals USA, Rockville, Maryland, USA) using a validated homogeneous solution based bridging enzyme linked immune sorbent assay (Mikulsis et al 2011, Qui et al 2010). The analysis of anti-reslizumab antibody in patient serum consists of 3 tiers of assays for screening, confirmation, and titer analysis. If a participant had a treatment-emergent ADA response (ie, ADA positive at any of the postdose time points but negative at the predose time point) or if there was a treatment-boosted ADA response (defined as a greater than 4-fold increase from a positive baseline ADA response (Shankar et at 2014), the participant was classified as overall ADA positive.\n\nPredose samples for the reslizumab-experienced participants came from the previous studies.", "populationDescription": "Safety analysis set of participants with assessments at stated timeframes", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, Weeks 24, 48, 72, 96, End of Study, Endpoint and Overall", "groups": [{"id": "OG000", "title": "Previous Placebo-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with placebo in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}, {"id": "OG001", "title": "Previous Reslizumab-Treated Subpopulation", "description": "The subpopulation of particpants who were treated with reslizumab at a variety of dosages in the previous double-blind studies. These participants were treated with resllizumab 3.0 mg/kg intravenously once every 4 weeks ( +-7 days) for up to 24 months in this study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "480"}, {"groupId": "OG001", "value": "571"}]}], "classes": [{"title": "Overall (n=466, 548)", "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "25"}]}]}, {"title": "Baseline (n=442, 541)", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "24"}]}]}, {"title": "Week 24 (n=382, 445)", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "13"}]}]}, {"title": "Week 48 (n=187, 247)", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Week 72 (n=56, 104)", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Week 96 (n=24, 48)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "End of study (n=142, 52)", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Endpoint (n=466, 545)", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "17"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observation, which included the 90 day follow-up visit.", "eventGroups": [{"id": "EG000", "title": "Reslizumab 3.0 mg/kg", "description": "Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months.", "seriousNumAffected": 78, "seriousNumAtRisk": 1051, "otherNumAffected": 519, "otherNumAtRisk": 1051}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Cardio-respiratory arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Coronary artery occlusion", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Coronary artery stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 1051}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Ventricular extrasystoles", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Amaurosis fugax", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Megacolon", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Pneumoperitoneum", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Small intestinal obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Umbilical hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Adverse drug reaction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Hernia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Suprapubic pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Cholangitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 1051}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Bronchitis pneumococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Infectious pleural effusion", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Infective exacerbation of bronchiectasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Mastoiditis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Otitis media acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Peritonitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 1051}]}, {"term": "Wound infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Hand fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Hip fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Lower limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Skull fractured base", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Spinal compression fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Tibia fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Liver function test abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Osteonecrosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Anal cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Borderline ovarian tumour", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 1051}]}, {"term": "Lymphoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Malignant melanoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 1051}]}, {"term": "Malignant melanoma in situ", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Metastases to lung", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Ovarian epithelial cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Carpal tunnel syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Nervous system disorder", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Aggression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Suicide attempt", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 1051}]}, {"term": "Stress urinary incontinence", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Urethral stenosis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Endometrial hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 24, "numAffected": 18, "numAtRisk": 1051}]}, {"term": "Asthmatic crisis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Haemoptysis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Haemothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 1051}]}, {"term": "Nasal septum deviation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Pleural effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Pneumonia aspiration", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Actinic keratosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Dermatitis atopic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Drug eruption", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}, {"term": "Hypovolaemic shock", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 1051}]}, {"term": "Shock haemorrhagic", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1051}]}], "otherEvents": [{"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 77, "numAffected": 62, "numAtRisk": 1051}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 226, "numAffected": 150, "numAtRisk": 1051}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 114, "numAffected": 77, "numAtRisk": 1051}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 141, "numAffected": 107, "numAtRisk": 1051}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 106, "numAffected": 73, "numAtRisk": 1051}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 563, "numAffected": 301, "numAtRisk": 1051}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data."}, "pointOfContact": {"title": "Director, Clinical Research", "organization": "Teva Branded Pharmaceutical Products, R&D Inc.", "email": "ustevatrials@tevapharm.com", "phone": "215-591-3000"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}, {"id": "D000011657", "term": "Pulmonary Eosinophilia"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000017681", "term": "Hypereosinophilic Syndrome"}, {"id": "D000004802", "term": "Eosinophilia"}, {"id": "D000007960", "term": "Leukocyte Disorders"}, {"id": "D000006402", "term": "Hematologic Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M14511", "name": "Pulmonary Eosinophilia", "asFound": "Eosinophilic Asthma", "relevance": "HIGH"}, {"id": "M7961", "name": "Eosinophilia", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M16355", "name": "Syndrome", "relevance": "LOW"}, {"id": "M19901", "name": "Hypereosinophilic Syndrome", "relevance": "LOW"}, {"id": "M10963", "name": "Leukocyte Disorders", "relevance": "LOW"}, {"id": "M9490", "name": "Hematologic Diseases", "relevance": "LOW"}, {"id": "T2886", "name": "Hypereosinophilic Syndrome", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC15", "name": "Blood and Lymph Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000515492", "term": "Reslizumab"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M10184", "name": "Immunoglobulins", "relevance": "LOW"}, {"id": "M4225", "name": "Antibodies", "relevance": "LOW"}, {"id": "M4230", "name": "Antibodies, Monoclonal", "relevance": "LOW"}, {"id": "M287460", "name": "Reslizumab", "asFound": "Diaphragmatic breathing exercises", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}